Multiple Sclerosis Treatment - Gilenya Usage Increasing At The Expense Of Extavia

BioTrends Research Group, Inc. concludes that Extavia, a treatment for Multiple Sclerosis, has been pushed to the back burner on the heels of a new product launch by Novartis called Gilenya. Gilenya is the first of its kind oral disease modifying agent used to combat MS. Since Gilenya hit the market, there has been a significant drop in patient prescriptions of Extavia.

However, it seems that polled neurologists do not think the frequency of their Extavia prescriptions will decrease over the next 6 months despite Novartis’ marketing of the new Gilenya alternative is expected to increase considerably.

According to LaunchTrends, a service used to evaluate new trials and product launches, Extavia has been tracked at four different intervals since its market launch - at 1 month, 6 months, 9 months, and 1 year. The research done presently has resulted in 76 neurologists questioned about prescription rates and a further set of questions to a subset of 20 neurologists in November 2010. The same tracking will be done on Gilenya over the next year with the first review to be publicly available in February 2011.

Tags: , , ,